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Immunogenicity of Ad26.COV2.S vaccine 
against SARS-CoV-2 variants in humans
 
Galit Alter1,2,9, Jingyou Yu1,9, Jinyan Liu1,9, Abishek Chandrashekar1,9, Erica N. Borducchi1,9, 
Lisa H. Tostanoski1,9, Katherine McMahan1,9, Catherine Jacob-Dolan1,3,9, David R. Martinez4, 
Aiquan Chang1,3, Tochi Anioke1, Michelle Lifton1, Joseph Nkolola1, Kathryn E. Stephenson1, 
Caroline Atyeo2,3, Sally Shin2, Paul Fields5, Ian Kaplan5, Harlan Robins5, Fatima Amanat6, 
Florian Krammer6, Ralph S. Baric4, Mathieu Le Gars7, Jerald Sadoff7, Anne Marit de Groot7, 
Dirk Heerwegh8, Frank Struyf8, Macaya Douoguih7, Johan van Hoof7, Hanneke Schuitemaker7 
& Dan H. Barouch1,2,3 ✉
The Ad26.COV2.S vaccine1–3 has demonstrated clinical efficacy against symptomatic 
COVID-19, including against the B.1.351 variant that is partially resistant to neutralizing 
antibodies1. However, the immunogenicity of this vaccine in humans against 
SARS-CoV-2 variants of concern remains unclear. Here we report humoral and cellular 
immune responses from 20 Ad26.COV2.S vaccinated individuals from the COV1001 
phase 1/2 clinical trial2 against the original SARS-CoV-2 strain WA1/2020 as well as 
against the B.1.1.7, CAL.20C, P.1., and B.1.351 variants of concern. Ad26.COV2.S 
induced median pseudovirus neutralizing antibody titers that were 5.0- and 3.3-fold 
lower against the B.1.351 and P.1 variants, respectively, as compared with WA1/2020 on 
day 71 following vaccination. Median binding antibody titers were 2.9- and 2.7-fold 
lower against the B.1.351 and P.1 variants, respectively, as compared with WA1/2020. 
Antibody-dependent cellular phagocytosis, complement deposition, and NK cell 
activation responses were largely preserved against the B.1.351 variant. CD8 and CD4 
T cell responses, including central and effector memory responses, were comparable 
among the WA1/2020, B.1.1.7, B.1.351, P.1, and CAL.20C variants. These data show that 
neutralizing antibody responses induced by Ad26.COV2.S were reduced against the 
B.1.351 and P.1 variants, but functional non-neutralizing antibody responses and T cell 
responses were largely preserved against SARS-CoV-2 variants. These findings have 
implications for vaccine protection against SARS-CoV-2 variants of concern.
SARS-CoV-2 variants that partially escape from neutralizing antibodies 
to the WA1/2020 strain have emerged, including the B.1.351 variant first 
identified in South Africa4,5. Such variants of concern may reduce the 
efficacy of current vaccines and natural immunity from SARS-COV-2 
strains that were prevalent at the beginning of the pandemic. The 
mRNA-1273 and BNT162b2 vaccines have been reported to induce lower 
neutralizing antibody titers against the B.1.351 variant than against the 
original WA1/2020 strain4,6,7. Additional SARS-CoV-2 variants include 
the B.1.1.7 variant first identified in the United Kingdom8, the P.1 and 
P.2 variants first identified in Brazil9, and the CAL.20C variant first 
identified in California10.
Ad26.COV2.S is a replication-incompetent human adenovirus 
type 26 (Ad26) vector11 expressing a prefusion stabilized SARS-CoV-2 
spike12 from the Wuhan 2019 strain, which is identical to the spike in 
the WA1/2020 strain. Ad26.COV2.S demonstrated protective efficacy 
against SARS-CoV-2 challenges in hamsters and nonhuman primates3,13 
and showed safety and immunogenicity in humans14,15. In the phase 3 
ENSEMBLE trial, a single dose of 5x1010 viral particles (vp) Ad26.COV2.S 
resulted in 72%, 68%, and 64% protection against moderate to severe 
COVID-19 and 86%, 88%, and 82% protection against severe/critical 
COVID-19 in the United States, Brazil, and South Africa, respectively, 
by day 28 following vaccination1. In this trial, 69% of sequenced viruses 
from confirmed COVID-19 cases in Brazil were the P.2 variant, and 95% 
of sequenced viruses from confirmed COVID-19 cases in South Africa 
were the B.1.351 variant, demonstrating that Ad26.COV2.S maintained 
protective efficacy against these SARS-CoV-2 variants.
COV1001 is a multicenter, randomized, double-blind, placebo- 
controlled Phase 1/2a trial to evaluate safety, reactogenicity and 
immunogenicity of Ad26.COV2.S at 5x1010 or 1x1011 vp administered 
intramuscularly as single-shot or two-shot vaccine schedules, 56 days 
apart, in healthy adults (NCT04436276)14. Cohort 1b enrolled 25 adults 
18-55 years of age from July 29, 2020 to August 7, 2020 at a single site 
at Beth Israel Deaconess Medical Center (BIDMC), Boston, MA for 
exploratory immunogenicity studies15. The study was approved by 
the BIDMC institutional review board, and all participants provided 
written informed consent. Participants were randomly allocated to one 
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of five experimental groups (N=5/group): (1) 5x1010 vp Ad26.COV2.S on 
day 1 and day 57 (low-dose/low-dose); (2) 5x1010 vp Ad26.COV2.S on day 
1 and placebo on day 57 as a single-shot vaccine (low-dose/placebo); 
(3) 1x1011 vp Ad26.COV2.S on day 1 and day 57 (high-dose/ high-dose); 
(4) 1x1011 vp Ad26.COV2.S on day 1 and placebo on day 57 as a single-shot 
vaccine (high-dose/placebo); or (5) placebo on day 1 and day 57 (pla-
cebo/placebo).
Antibody Responses to Variants
Antibody responses were assessed against the SARS-CoV-2 WA1/2020 
strain as well as against B.1.351 and other variants of concern. Using a 
luciferase-based pseudovirus neutralizing antibody (psVNA) assay3,16,17, 
the median psVNA titers were 169, 142, 102, 80, 60, and 51 against the 
WA1/2020, D614G, B.1.1.7, CAL.20C, P.1, and B.1.351 strains, respectively, 
on day 57 (Fig. 1a). The median psVNA titers were 340, 190, 121, 133, 
102, and 67, respectively, against these variants on day 71. These data 
show a 3.3-fold reduction of psVNA titers against P.1 and a 5.0-fold 
reduction of psVNA titers against B.1.351 as compared with WA1/2020 
on day 71. No psVNA titers were observed in placebo recipients. Live 
virus neutralizing antibody assays18 showed a greater 10.6-fold reduc-
tion in antibody titers against B.1.351 as compared with WA1/2020 on 
day 71 (Extended Data Fig. 1). This study was not powered to compare 
responses for the different vaccine doses or regimens.
On day 57, median receptor binding domain (RBD)-specific bind-
ing antibody ELISA titers were 1772, 1364, 486, and 392 against the 
WA1/2020, B.1.1.7, P.1., and B.1.351 variants, respectively (Fig. 1b). On 
day 71, median ELISA titers were 1962, 1682, 714, and 683, respectively, 
against these variants. These data show a 1.2-, 2.7-, and 2.9-fold reduc-
tion of ELISA titers against B.1.1.7, P.1, and B.1.351 RBD, respectively, as 
compared with WA1/2020 RBD on day 71. Minimal ELISA titers were 
observed in placebo recipients.
An electrochemiluminescence assay (ECLA)19 was also used to 
evaluate Spike (S)- and RBD-specific binding antibody responses to 
WA1/2020, B.1.1.7, P.1., and B.1.351 (Fig. 1c). Similar to the ELISA titers, 
median RBD-specific ECLA responses against B.1.1.7, P.1, and B.1.351 
were reduced 1.3-, 1.8-, and 2.9-fold, and median S-specific ECLA 
responses were reduced 1.6-, 1.8-, and 2.6-fold, respectively, as com-
pared with WA1/2020 on day 71.
Antibody Fc effector function was assessed on day 71 by sys-
tems serology20, including antibody-dependent cellular phago-
cytosis (ADCP), antibody-dependent neutrophil phagocytosis 
(ADNP), antibody-dependent complement deposition (ADCD), and 
antibody-dependent NK cell activation (ADNKA). S-specific ADCP, 
ADNP, ADCD, and ADNKA responses against the B.1.351 variant were 
1.5-, 2.9-, 1.6-, and 1.1-fold reduced, respectively, compared with the 
WA1/2020 strain with the D614G mutation (Fig. 2a). Comparable 
IgG, IgM, and IgA subclasses and Fc-receptor binding were observed 
across the variants, with only a slight loss in FcγR2b binding com-
pared to the WA1/2020 strain (Fig. 2b). RBD-specific ADCP, ADNP, 
and ADCD responses were comparable against the WA1/2020, B.1.1.7, 
and B.1.351 variants (Extended Data Fig. 2). These data show robust 
S- and RBD-specific Fc-effector functions against these SARS-CoV-2 
variants.
Cellular Immune Responses to Variants
S-specific cellular immune responses were assessed by pooled peptide 
ELISPOT assays in peripheral blood mononuclear cells (PBMC) on days 
57 and 85. IFN-γ ELISPOT responses were comparable to WA1/2020, 
B.1.351, B.1.1.7, P.1, and CAL.20C at both timepoints, with no evidence 
of decreased responses against the variants (Fig. 3a). No S-specific 
ELISPOT responses were observed in placebo recipients. S-specific 
CD8+ and CD4+ T cell responses were evaluated by multiparameter 
intracellular cytokine staining (ICS) assays on days 57 and 85 (Extended 
Data Fig. 3). IFN-γ CD8+ and CD4+ T cell responses were comparable 
to WA1/2020, B.1.351, B.1.1.7, P.1, and CAL.20C variants (Fig. 3b). The 
median ratios of B.1.351, B.1.1.7, and P.1 to WA1/2020 IFN-γ CD8+ T cell 
responses were 0.98, 0.98, and 0.98, respectively, on day 57 and 0.92, 
0.94, and 1.26, respectively, on day 85 (Extended Data Fig. 4). Central 
memory CD27+CD45RA- and effector memory CD27-CD45RA- CD4+ 
and CD8+ T cell responses were also comparable across these vari-
ants (Extended Data Figs. 5-6). These data show that S-specific cellular 
immune responses were not detectably impacted by SARS-CoV-2 vari-
ants. Polyfunctional analyses showed that CD8+ T cells were primar-
ily IFN-γ, TNF-α, and IFN-γ/TNF-α responses, whereas CD4+ T cells 
were primarily TNF-α, IFN-γ/TNF-α, IL-2/TNF-α, and IFN-γ/IL-2/TNF-α 
responses (Extended Data Fig. 7).
To evaluate the specificity and breadth of individual T-cell receptors 
(TCRs) following vaccination, TCRβ sequencing21 was performed to 
define the repertoires of 8 convalescent individuals and 19 vaccine and 
5 placebo participants on day 63 (Extended Data Table 1). To identify 
SARS-CoV-2 specific TCRs, the observed TCRs were compared to a TCR 
dataset that had previously been determined to be SARS-CoV-2-specific 
and enriched in subjects with natural infection relative to placebos22. 
The breadth (unique rearrangements) and depth (frequency of TCRs) 
of TCRs specific to either Spike (S) or non-Spike SARS-CoV-2 proteins 
were determined, although these analyses may have underestimated 
total T cell responses. Higher breadth of S-specific TCRs was observed 
in vaccine recipients compared with placebos (P=0.0014, Wilcoxon 
rank-sum test; Fig. 4a; Extended Data Figs. 8-9). In contrast, the breadth 
of non-Spike TCRs was comparable in vaccine recipients and controls, 
as expected since the vaccine did not contain any non-Spike immuno-
gens. Substantial breadth of CD8+ and CD4+ T cell responses was also 
observed (Fig. 4b).
Discussion
SARS-CoV-2 variants have emerged with multiple mutations in targets 
of neutralizing antibodies, such as the E484K mutation. Median pseu-
dovirus neutralizing antibody titers induced by Ad26.COV2.S were 
5.0-fold lower against the B.1.351 variant and 3.3-fold lower against 
the P.1 variant as compared with the original WA1/2020 strain, which 
is a comparable reduction of psVNA titers that has been reported for 
other vaccines4,6,7. In contrast, functional non-neutralizing antibody 
responses and CD8+ and CD4+ T cell responses were largely preserved 
against SARS-CoV-2 variants of concern.
In the phase 3 ENSEMBLE trial1, Ad26.COV2.S was evaluated in the 
United States, Latin America including Brazil, and South Africa. In South 
Africa, 95% of sequenced viruses from COVID-19 cases were of the B.1.351 
variant, and in Brazil, 69% of sequenced viruses from COVID-19 cases 
were of the P.2 lineage. Protective efficacy of Ad26.COV2.S against 
severe/critical disease was similar in all geographic locations by day 
28, and protective efficacy against moderate to severe disease was only 
slightly reduced in South Africa and Brazil compared with the United 
States. Although the mechanistic correlates of protection for COVID-
19 are not yet known, the robust protective efficacy in these regions 
despite reduced neutralizing antibodies raises the possibility that 
functional non-neutralizing antibodies and/or CD8+ T cell responses 
may also contribute to protection. Indeed, TCRβ sequencing revealed 
substantial breadth of T cell responses in individuals vaccinated with 
Ad26.COV2.S. Alternatively, it is possible that low levels of neutralizing 
antibodies are sufficient for protection. In a nonhuman primate model, 
adoptive transfer of purified IgG was sufficient for protection against 
SARS-CoV-2 if psVNA titers exceeded a threshold of approximately 
50, but CD8+ T cells also contributed to protection if antibody titers 
were subprotective23.
In conclusion, neutralizing antibody responses elicited by Ad26.
COV2.S were reduced against the B.1.351 and P.1 variants, but other func-
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against these variants. The relevance of these immune parameters to 
mechanistic correlates of vaccine efficacy remains to be determined.
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Fig. 1 | Neutralizing and binding antibody responses to SARS-CoV-2 
variants. (a) SARS-CoV-2 pseudovirus neutralizing antibody (psVNA) 
responses against WA1/2020, D614G, B.1.1.7, CAL.20C, P.1, and B.1.351,  
(b) receptor binding domain (RBD)-specific binding antibodies by ELISA 
against WA1/2020, B.1.1.7, P.1, and B.1.351, and (c) RBD- and S-specific binding 
antibodies by electrochemiluminescence assay (ECLA) against WA1/2020, 
B.1.1.7, P.1, and B.1.351 (Meso Scale Discovery Panel 7) on day 57 and day 71. Red 
bars reflect median responses. Dotted lines reflect lower limits of quantitation. 
Filled squares, placebo-placebo; filled circles, high dose-placebo; open circles, 
high dose-high dose; filled triangles, low dose-placebo; open triangles, low 
dose-low dose. n=25 independent samples (5 placebo recipients, 20 Ad26.
COV2.S vaccine recipients).




























Fig. 2 | Systems serology to SARS-CoV-2 variants. (a) S-specific ADCP 
(antibody-dependent cellular phagocytosis), ADNP (antibody-dependent 
neutrophil phagocytosis), ADCD (antibody-dependent complement 
deposition), and ADNKA (antibody-dependent NK cell activation) against 
WA1/2020 (D614G), B.1.1.7, and B.1.351 on day 71. Red bars reflect median 
responses. Dotted lines reflect median of placebo recipients. Filled circles, 
high dose-placebo; open circles, high dose-high dose; filled triangles, low 
dose-placebo; open triangles, low dose-low dose. (b) The nightingale plots 
show the median levels of WA1/2020 (D614G), B.1.1.7, B.1.351 S-specific isotype 
(IgM, IgA, IgG1, IgG2, IgG3) (red) and FcγR2a, FcγR2b, FcγR3a (blue) binding. 
n=20 independent samples from Ad26.COV2.S vaccine recipients.



























Fig. 3 | See next page for caption.




























Fig. 3 | Cellular immune responses to SARS-CoV-2 variants. (a) S-specific 
pooled peptide IFN-γ ELISPOT responses against WA1/2020, B.1.351, B.1.1.7, P.1, 
and CAL.20C. n=25 independent samples (5 placebo recipients, 20 Ad26.
COV2.S vaccine recipients). (b) S-specific pooled peptide IFN-γ CD4+ and CD8+ 
T cell responses by intracellular cytokine staining (ICS) assays against 
WA1/2020, B.1.351, B.1.1.7, P.1, and CAL.20C. SFC, spot-forming cells. 
Responses are shown on day 57 and day 85. Red bars reflect median responses. 
Dotted lines reflect lower limits of quantitation. Filled squares, 
placebo-placebo; filled circles, high dose-placebo; open circles, high dose-high 
dose; filled triangles, low dose-placebo; open triangles, low dose-low dose. 
n=20 independent samples from Ad26.COV2.S vaccine recipients.



























Fig. 4 | TCRβ repertoire analysis. (a) Spike and non-Spike T cell breadth by 
TCRβ sequencing on day 63. P-values represent 2-sided Wilcoxon rank-sum 
tests. Red bars reflect median responses. (b) Breadth of Spike-specific CD8+ 
and CD4+ T cell responses. Filled squares, placebo-placebo; filled circles, high 
dose-placebo; open circles, high dose-high dose; filled triangles, low 
dose-placebo; open triangles, low dose-low dose; plus signs, convalescent 
samples. In the box-and-whisker plots, the middle line reflects the median, the 
box reflects the 25-75 percentiles, and the whiskers extend the full range up to 
1.5x the interquartile range, with outlier points marked individually. n=32 
independent samples (8 SARS-CoV-2 convalescent individuals, 5 placebo 
recipients, 19 Ad26.COV2.S vaccine recipients).






























The SARS-CoV-2 pseudoviruses expressing a luciferase reporter gene 
were generated in an approach similar to as described previously17,24. 
Briefly, the packaging plasmid psPAX2 (AIDS Resource and Reagent 
Program), luciferase reporter plasmid pLenti-CMV Puro-Luc (Addgene), 
and spike protein expressing pcDNA3.1-SARS CoV-2 SΔCT of variants 
were co-transfected into HEK293T cells by lipofectamine 2000 (Ther-
moFisher). Pseudoviruses of SARS-CoV-2 variants were generated by 
using WA1/2020 strain (Wuhan/WIV04/2019, GISAID accession ID: 
EPI_ISL_402124), D614G mutation, B.1.1.7 variant (GISAID accession ID: 
EPI_ISL_601443), CAL.20C (GISAID accession ID: EPI_ISL_824730), P.1 
(GISAID accession ID: EPI_ISL_792683), or B.1.351 variant (GISAID acces-
sion ID: EPI_ISL_712096). The supernatants containing the pseudotype 
viruses were collected 48 h post-transfection, which were purified by 
centrifugation and filtration with 0.45 µm filter. To determine the neu-
tralization activity of the plasma or serum samples from participants, 
HEK293T-hACE2 cells were seeded in 96-well tissue culture plates at a 
density of 1.75 x 104 cells/well overnight. Three-fold serial dilutions of 
heat inactivated serum or plasma samples were prepared and mixed 
with 50 µL of pseudovirus. The mixture was incubated at 37 °C for 1 h 
before adding to HEK293T-hACE2 cells. 48 h after infection, cells were 
lysed in Steady-Glo Luciferase Assay (Promega) according to the manu-
facturer’s instructions. SARS-CoV-2 neutralization titers were defined 
as the sample dilution at which a 50% reduction in relative light unit 
(RLU) was observed relative to the average of the virus control wells.
Live virus neutralization assay
Full-length SARS-CoV-2 WA1/2020, B.1.351, and B.1.1.7, viruses were 
designed to express nanoluciferase (nLuc) and were recovered via 
reverse genetics18. One day prior to the assay, Vero E6 USAMRID cells 
were plated at 20,000 cells per well in clear bottom black walled plates. 
Cells were inspected to ensure confluency on the day of assay. Serum 
samples were tested at a starting dilution of 1:20 and were serially 
diluted 3-fold up to nine dilution spots. Serially diluted serum samples 
were mixed in equal volume with diluted virus. Antibody-virus and 
virus only mixtures were then incubated at 37 °C with 5% CO2 for one 
hour. Following incubation, serially diluted sera and virus only controls 
were added in duplicate to the cells at 75 PFU at 37 °C with 5% CO2. 
Twenty four hours later, the cells were lysed, and luciferase activity was 
measured via Nano-Glo Luciferase Assay System (Promega) according 
to the manufacturer specifications. Luminescence was measured by a 
Spectramax M3 plate reader (Molecular Devices, San Jose, CA). Virus 
neutralization titers were defined as the sample dilution at which a 
50% reduction in RLU was observed relative to the average of the virus 
control wells.
ELISA
WA1/2020, B.1.1.7, and B.1.351 RBD-specific binding antibodies were 
assessed by ELISA. Briefly, 96-well plates were coated with 2µg/ml RBD 
proteins (provided by Dr. Florian Krammer) in 1X DPBS and incubated 
at 4 °C overnight. After incubation, plates were washed once with wash 
buffer (0.05% Tween 20 in 1 X DPBS) and blocked with 350 µL Casein 
block/well for 2-3 h at room temperature. After incubation, block 
solution was discarded and plates were blotted dry. Serial dilutions 
of heat-inactivated serum diluted in casein block were added to wells 
and plates were incubated for 1 h at room temperature, prior to three 
further washes and a 1 h incubation with a 1:4000 dilution of anti-human 
IgG HRP (Invitrogen) at room temperature in the dark. Plates were 
then washed three times, and 100 µL of SeraCare KPL TMB SureBlue 
Start solution was added to each well; plate development was halted 
by the addition of 100 µL SeraCare KPL TMB Stop solution per well. The 
absorbance at 450nm, with a reference at 650nm, was recorded using 
a VersaMax microplate reader. For each sample, ELISA endpoint titer 
was calculated in Graphpad Prism software, using a four-parameter 
logistic curve fit to calculate the reciprocal serum dilution that yields 
a corrected absorbance value (450nm-650nm) of 0.2. Log10 endpoint 
titers are reported.
Electrochemiluminescence assay (ECLA)
ECLA plates (MesoScale Discovery SARS-CoV-2 IgG Cat No: N05CA-
1; Panel 7) were designed and produced with up to 9 antigen spots in 
each well. The antigens included were WA1/2020, B.1.1.7, P.1, and B.1.351 
S and RBD. The plates were blocked with 50 uL of Blocker A (1% BSA 
in MilliQ water) solution for at least 30 m at room temperature shak-
ing at 700 rpm with a digital microplate shaker. During blocking the 
serum was diluted 1:5,000 in Diluent 100. The plates were then washed 
3 times with 150 µL of the MSD kit Wash Buffer, blotted dry, and 50 µL 
of the diluted samples were added in duplicate to the plates and set 
to shake at 700 rpm at room temperature for at least 2 h. The plates 
were again washed 3 times and 50 µL of SULFO-Tagged anti-Human IgG 
detection antibody diluted to 1x in Diluent 100 was added to each well 
and incubated shaking at 700 rpm at room temperature for at least 1 h. 
Plates were then washed 3 times and 150 µL of MSD GOLD Read Buffer 
B was added to each well and the plates were read immediately after 
on a MESO QuickPlex SQ 120 machine. MSD titers for each sample 
was reported as Relative Light Units (RLU) which were calculated as 
Sample RLU minus Blank RLU for each spot for each sample. The limit 
of detection was defined as 1000 RLU for each assay.
Systems Serology
Both the biophysical and functional quality of polyclonal vaccine 
induced SARS-CoV-2 antibodies were profiled using systems serology20. 
Biophysical profiling was performed using a custom Luminex based 
assay where individuals bar-coded beads were coated with Spike (S) 
or (RBD) variants by carboxy coupling. The D614G, B.1.1.7 and B.1.351 
variants (provided by Drs. Erica Ollman Saphire and Florian Kram-
mer) were profiled. The overall levels of IgG1, IgG2, IgG3, IgA, IgM and 
FcγR2a, FcγR2b, FcγR3a, and FcγR3b binding were assessed. Functional 
profiling included the assessment of antibody dependent monocyte 
phagocytosis (ADCP), antibody dependent neutrophil phagocyto-
sis (ADNP), antibody dependent complement deposition (ADCD), 
and antibody dependent NK cell activation (ADNKA). Briefly, for the 
ADCP, ADNP, and ADCD assays, fluorescent beads (LifeTechnologies) 
were coupled via carboxy-coupling, and plasma were added, allowing 
immune complex formation, excess antibodies were washed away, 
followed by the addition of THP1 monocytes, primary neutrophils, or 
guinea pig complement, individually, respectively. The level of phago-
cytosis and complement deposition was assessed by flow cytometry. 
For ADNKA, ELISA plates were coated with antigen, followed by the 
addition of plasma. Excess antibodies were washed away following by 
the addition of primary NK cells. NK cells were treated with Golgi Stop 
(BD) and Brefeldin A (Sigma Aldrich) and were stained for the surface 
markers CD56, CD16 and CD3 and for activity markers CD107a (BD) 
and MIP-1b (BD). Fluorescence was determined by flow cytometry. NK 
cells were classified as CD56+/CD16+/CD3-.
Enzyme-linked immunospot (ELISPOT) assay
ELISPOT plates were coated with mouse anti-human IFN-γ monoclonal 
antibody from MabTech at 1 µg/well and incubated overnight at 4 °C. 
Plates were washed with DPBS, and blocked with R10 media (RPMI 
with 10% heat inactivated FBS with 1% of 100x penicillin-streptomycin, 
1M HEPES, 100mM Sodium pyruvate, 200mM L-glutamine, and 0.1% 
of 55mM 2-Mercaptoethanol) for 2-4 h at 37 °C. SARS-CoV-2 pooled S 
peptides from WA1/2020, B.1.351, B.1.1.7, P.1, and CAL.20C (21st Century 
Biochemicals) were prepared and plated at a concentration of 2 µg/well, 
and 100,000 cells/well were added to the plate. The peptides and cells 
were incubated for 15-20 h at 37 °C. All steps following this incubation 


























ELISPOT wash buffer and incubated for 2-4 h with Biotinylated mouse 
anti-human IFN-γ monoclonal antibody from MabTech (1 µg/mL). 
The plates were washed a second time and incubated for 2-3 h with 
conjugated Goat anti-biotin AP from Rockland, Inc. (1.33 µg/mL). 
The final wash was followed by the addition of Nitor-blue Tetrazo-
lium Chloride/5-bromo-4-chloro 3 ‘indolyphosphate p-toludine salt 
(NBT/BCIP chromagen) substrate solution for 7 min. The chromagen 
was discarded and the plates were washed with water and dried in a dim 
place for 24 h. Plates were scanned and counted on a Cellular Technolo-
gies Limited Immunospot Analyzer.
Intracellular cytokine staining (ICS) assay
106 PBMCs/well were re-suspended in 100 µL of R10 media supple-
mented with CD49d monoclonal antibody (1 µg/mL) and CD28 mono-
clonal antibody (1 µg/mL). Each sample was assessed with mock (100 µL 
of R10 plus 0.5% DMSO; background control), pooled S peptides from 
WA1/2020, B.1.351, B.1.1.7, P.1, and CAL.20C (21st Century Biochemicals) 
(2 µg/mL), or 10 pg/mL phorbol myristate acetate (PMA) and 1 µg/mL 
ionomycin (Sigma-Aldrich) (100µL; positive control) and incubated 
at 37 °C for 1 h. After incubation, 0.25 µL of GolgiStop and 0.25 µL of 
GolgiPlug in 50 µL of R10 was added to each well and incubated at 37 °C 
for 8 h and then held at 4 °C overnight. The next day, the cells were 
washed twice with DPBS, stained with aqua live/dead dye for 10 mins 
and then stained with predetermined titers of mAbs against CD279 
(clone EH12.1, BB700), CD4 (clone L200, BV711), CD27 (clone M-T271, 
BUV563), CD8 (clone SK1, BUV805), CD45RA (clone 5H9, APC H7) for 
30 min. Cells were then washed twice with 2% FBS/DPBS buffer and 
incubated for 15 min with 200µL of BD CytoFix/CytoPerm Fixation/
Permeabilization solution. Cells were washed twice with 1X Perm Wash 
buffer (BD Perm/WashTM Buffer 10X in the CytoFix/CytoPerm Fixation/ 
Permeabilization kit diluted with MilliQ water and passed through 
0.22µm filter) and stained with intracellularly with mAbs against Ki67 
(clone B56, BB515), IL21 (clone 3A3-N2.1, PE), CD69 (clone TP1.55.3, 
ECD), IL10 (clone JES3-9D7, PE CY7), IL13 (clone JES10-5A2, BV421), IL4 
(clone MP4-25D2, BV605), TNF-α (clone Mab11, BV650), IL17 (clone N49-
653, BV750), IFN-γ (clone B27; BUV395), IL2 (clone MQ1-17H12, BUV737), 
IL6 (clone MQ2-13A5, APC), CD3 (clone SP34.2, Alexa 700), for 30 min. 
Cells were washed twice with 1X Perm Wash buffer and fixed with 250µL 
of freshly prepared 1.5% formaldehyde. Fixed cells were transferred 
to 96-well round bottom plate and analyzed by BD FACSymphonyTM 
system. Data were analyzed with FlowJo v9.9.
T-cell receptor variable beta chain sequencing
Immunosequencing of the CDR3 regions of human TCRβ chains was 
performed using the immunoSEQ® Assay (Adaptive Biotechnologies, 
Seattle, WA). Extracted genomic DNA was amplified in a bias-controlled 
multiplex PCR, followed by high-throughput sequencing. Sequences 
were collapsed and filtered in order to identify and quantitate the abso-
lute abundance of each unique TCRβ CDR3 region for further analy-
sis as previously described21. The fraction of T cells was calculated by 
normalizing TCRβ template counts to the total amount of DNA usable 
for TCR sequencing, where the amount of usable DNA was determined 
by PCR-amplification and sequencing of several reference genes that 
are expected to be present in all nucleated cells. TCR sequences from 
repertoires were mapped against a set of TCR sequences that are known 
to react to SARS-CoV-2 by matching on V gene, amino acid sequence 
and J gene. Briefly, these sequences were first identified by Multiplex 
Identification of T-cell Receptor Antigen Specificity (MIRA)22. TCRs 
that react were further screened for enrichment in COVID-19 positive 
repertoires collected as part of ImmuneCODE compared to COVID-
19 negative repertoires to remove TCRs that may be highly public or 
cross-reactive to common antigens. Individual response could be 
quantified by the number and/or frequency of SARS-CoV-2 TCRs seen 
post-vaccine. TCRs were further analyzed at the level specific ORF or 
position within ORF based on the MIRA antigens. The breadth summary 
metric is calculated as the number of unique annotated rearrangements 
out of the total number of unique productive rearrangements, while 
depth summary metric corresponds to the sum frequency of those 
rearrangements in the repertoire. Sequences of known variants were 
obtained from GISAID (www.gisaid.org) and aligned to known MIRA 
antigen locations.
Reporting summary
Further information on research design is available in the Nature 
Research Reporting Summary linked to this paper.
Data availability
All data are available in the manuscript and supplementary information.
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Extended Data Fig. 1 | Live virus neutralizing antibody responses to 
SARS-CoV-2 variants. SARS-CoV-2 live virus neutralizing antibody responses 
against WA1/2020, B.1.1.7, and B.1.351. Red bars reflect median responses. 
Dotted lines reflect lower limits of quantitation. Filled squares, 
placebo-placebo; filled circles, high dose-placebo; open circles, high dose-high 
dose; filled triangles, low dose-placebo; open triangles, low dose-low dose. 




























Extended Data Fig. 2 | RBD-specific functional antibody responses to 
SARS-CoV-2 variants. Top, RBD-specific ADCP (antibody-dependent cellular 
phagocytosis), ADNP (antibody-dependent neutrophil phagocytosis), and 
ADCD (antibody-dependent complement deposition) against WA1/2020 
(D614G), B.1.1.7, and B.1.351. LD, low dose; HD, high dose; PL, placebo on day 71. 
Filled circles, high dose-placebo; open circles, high dose-high dose; filled 
triangles, low dose-placebo; open triangles, low dose-low dose. Bottom, 
RBD-specific isotype (IgG1, IgG3, IgA, IgM) (red) and FcγR2a, FcγR2b, FcγR3a 
(blue) binding against WA1/2020 (D614G), B.1.1.7, B.1.351 on day 71. n=20 























































Extended Data Fig. 4 | Ratio of variants vs. WA1/2020 CD8+ T cell responses. 
Ratio of S-specific pooled peptide IFN-γ CD8+ T cell responses by intracellular 
cytokine staining (ICS) assays against B.1.351, B.1.1.7, and P.1 vs. WA1/2020 on 
day 57 and day 85. Red bars reflect median responses. Filled circles, high 
dose-placebo; open circles, high dose-high dose; filled triangles, low 
dose-placebo; open triangles, low dose-low dose. n=20 independent samples 




























Extended Data Fig. 5 | Central and effector memory CD8+ T cell responses 
to SARS-CoV-2 variants. S-specific pooled peptide IFN-γ central memory 
CD27+CD45RA- and effector memory CD27-CD45RA- CD8+ T cell responses by 
intracellular cytokine staining (ICS) assays against WA1/2020, B.1.351, B.1.1.7, 
P.1, and CAL.20C on day 57 and day 85. Red bars reflect median responses. 
Dotted lines reflect lower limits of quantitation. Filled circles, high 
dose-placebo; open circles, high dose-high dose; filled triangles, low 
dose-placebo; open triangles, low dose-low dose. n=20 independent samples 



























Extended Data Fig. 6 | Central and effector memory CD4+ T cell responses 
to SARS-CoV-2 variants. S-specific pooled peptide IFN-γ central memory 
CD27+CD45RA- and effector memory CD27-CD45RA- CD4+ T cell responses by 
intracellular cytokine staining (ICS) assays against WA1/2020, B.1.351, B.1.1.7, 
P.1, and CAL.20C on day 57 and day 85. Red bars reflect median responses. 
Dotted lines reflect lower limits of quantitation. Filled circles, high 
dose-placebo; open circles, high dose-high dose; filled triangles, low 
dose-placebo; open triangles, low dose-low dose. n=20 independent samples 




























Extended Data Fig. 7 | Polyfunctional CD8+ and CD4+ T cell responses. 
WA1/2020 S-specific pooled peptide monofunctional and multifunctional 
IFN-γ, IL-2, and TNF-α CD8+ and CD4+ T cell responses by intracellular cytokine 
staining (ICS) assays on day 57 and day 85. Red bars reflect median responses. 
Dotted lines reflect lower limits of quantitation. Filled circles, high 
dose-placebo; open circles, high dose-high dose; filled triangles, low 
dose-placebo; open triangles, low dose-low dose. n=20 independent samples 



























Extended Data Fig. 8 | CD8+ TCRβ repertoire analysis. CD8+ T cell breadth 
and depth by TCRβ sequencing on day 57. Red bars reflect median responses. 
Filled squares, placebo-placebo; filled circles, high dose-placebo; open circles, 
high dose-high dose; filled triangles, low dose-placebo; open triangles, low 
dose-low dose; plus signs, convalescent samples. n=32 independent samples  





























Extended Data Fig. 9 | CD4+ TCRβ repertoire analysis. CD4+ T cell breadth 
and depth by TCRβ sequencing on day 57. Red bars reflect median responses. 
Filled squares, placebo-placebo; filled circles, high dose-placebo; open circles, 
high dose-high dose; filled triangles, low dose-placebo; open triangles, low 
dose-low dose; plus signs, convalescent samples. n=32 independent samples  




























Extended Data Table 1 | TCRβ repertoire analysis
Cell parameters analyzed for TCRβ sequencing. n=32 independent samples (8 SARS-CoV-2 convalescent individuals, 5 placebo recipients, 19 Ad26.COV2.S vaccine recipients).
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